WO2021045242A2 - 구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 - Google Patents
구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 Download PDFInfo
- Publication number
- WO2021045242A2 WO2021045242A2 PCT/KR2019/011306 KR2019011306W WO2021045242A2 WO 2021045242 A2 WO2021045242 A2 WO 2021045242A2 KR 2019011306 W KR2019011306 W KR 2019011306W WO 2021045242 A2 WO2021045242 A2 WO 2021045242A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- composition
- gujeolcho
- malt
- premenstrual syndrome
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- the present specification relates to a composition for improvement, prevention or treatment of premenstrual syndrome comprising Gujeolcho extract as an active ingredient.
- premenstrual syndrome can be diagnosed when one or more of the 7 symptoms of muscular tension or aches), poor concentration, and change in appetite are satisfied and these symptoms are confined to the luteal phase of the menstrual cycle. This is a symptom that appears from 4 to 7 days before menstruation to before menstruation, and symptoms disappear completely with the onset of menstruation. Therefore, it is classified as a different disease from menstrual pain that occurs when the endometrium is peeled off during the menstrual period.
- premenstrual syndrome has not been clearly identified, but lifestyle habits such as hormonal imbalance and genetic propensity, ovulation menstrual cycle, drug use, smoking, alcohol and caffeine consumption, eating patterns, taking contraceptives, emotional state and marital status. And social factors, as well as age, height and weight, birth and menstrual history, and stress are also known to be related to premenstrual syndrome.
- lifestyle habits such as hormonal imbalance and genetic propensity, ovulation menstrual cycle, drug use, smoking, alcohol and caffeine consumption, eating patterns, taking contraceptives, emotional state and marital status.
- social factors, as well as age, height and weight, birth and menstrual history, and stress are also known to be related to premenstrual syndrome.
- female hormones and progesterone which change according to the menstrual cycle, affect various cranial nerve transport substances. It has been reported that it can lead to the occurrence of premenstrual syndrome.
- Prolactin is a milk secretion stimulating hormone secreted from coral cells of the anterior pituitary gland, and is known to be increased by estrogen and decreased by dopamine secreted from the hypothalamus.
- the secretion of progesterone is higher than estrogen in the luteal phase, so that the secretion of prolactin is stabilized, but in the case of women with premenstrual syndrome, the secretion of progesterone is lower than that of estrogen, thereby increasing the secretion of prolactin. It has been reported to induce the syndrome (Halbreich et al., 1976).
- prefemin tablet (Agnus castus fruit extract), which has an effect of inhibiting prolactin secretion, is marketed as a representative premenstrual syndrome treatment, and in clinical trials, it relieves symptoms such as irritation, depression, anger, headache, and breast pain. It is known that it has improved by 50%.
- Patent Document 1 Korean Patent Publication No. 10-2013-0076114
- Patent Document 2 Korean Laid-Open Patent No. 10-2010-0044433
- Patent Document 3 Korean Laid-Open Patent No. 10-2013-0092256
- the present inventors recognized the importance of prevention and treatment for female premenstrual syndrome, and selected natural resources that exhibit the efficacy of inhibiting prolactin secretion in pituitary cells and the efficacy of pituitary cell proliferation using various natural materials.
- Gujeolcho extract strongly inhibited the secretion of prolactin in the pituitary gland cells, and mixtures with malt extract, malt extract, and aloe extract showed more inhibitory effect on prolactin secretion compared to Gujeolcho alone extract.
- compositions in the hyperprolactinemia-inducing animal model effectively regulate the secretion of progesterone, and thus have a great potential for commercialization as a composition for the prevention, improvement, or treatment of premenstrual syndrome caused by the reversal of estrogen and progesterone.
- an object of the present invention is to provide a pharmaceutical composition for preventing, improving or treating premenstrual syndrome comprising a mixture of Gujeolcho extract, Gujeolcho extract and malt extract, Gujeolcho extract, and a mixture of malt extract and aloe extract.
- Another object of the present invention is to provide a health functional food composition for preventing and improving premenstrual syndrome symptoms, including a mixture of Gujeolcho extract, Gujeolcho extract and malt extract, Gujeolcho extract, and a mixture of malt extract and aloe extract.
- One aspect of the present invention provides a composition for improving, preventing or treating premenstrual syndrome, comprising a Gujeolcho extract as an active ingredient.
- the composition provides a composition further comprising a malt extract.
- the composition provides a composition further comprising an aloe extract in addition to the malt extract.
- the extract provides a composition, which is a water extract, a C 1 -C 5 alcohol extract or a C 1 -C 5 alcohol aqueous solution extract.
- the Gujeolcho extract provides a composition of 0.001 to 90% by weight based on the total weight of the composition.
- the malt extract provides a composition comprising 50 to 150 parts by weight based on 100 parts by weight of Gujeolcho extract.
- the malt extract is included in an amount of 50 to 150 parts by weight based on 100 parts by weight of Gujeolcho extract
- the aloe extract is included in an amount of 10 to 30 parts by weight based on 100 parts by weight of Gujeolcho extract. do.
- the Gujeolcho extract is a 60% to 80% ethanol aqueous solution extract
- the malt extract is a 40% to 60% ethanol aqueous solution extract
- the aloe extract is a 20% to 40% ethanol aqueous solution extract
- composition Provides.
- the composition provides a composition, characterized in that it suppresses the secretion of prolactin or increases the secretion of progesterone in a woman in the luteal phase before menstruation.
- the symptoms of the premenstrual syndrome are minor psychological discomfort, bloating, weight gain, breast tenderness, muscle pain (muscular tension or aches). , Poor concentration and appetite change (change in appetite) any one or more of, and the premenstrual syndrome symptom is characterized in that it appears only in the luteal phase of the menstrual cycle, it provides a composition.
- the composition for preventing or treating premenstrual syndrome provides a pharmaceutical composition, a composition.
- the composition for improving the premenstrual syndrome provides a health functional food composition, a composition.
- Gujeolcho extract contained as an active ingredient in the composition of the present invention effectively inhibits the secretion of prolactin in the pituitary gland cells, and increases the secretion of progesterone in the luteal phase.
- the composition of the above Gujeolcho extract as an active ingredient in a mixture of malt extract or malt extract and aloe extract inhibits the secretion of prolactin in the pituitary gland cells and more effectively controls the secretion of progesterone.
- Gujeolcho extract or a mixture of Gujeolcho extract and malt extract, or a mixture of Gujeolcho extract and malt extract and aloe extract can improve, prevent or treat diseases that require inhibition of prolactin secretion and increase secretion of progesterone, that is, premenstrual syndrome. .
- variable includes all values within the stated range, including the stated endpoints of the range.
- a range of “5 to 10” includes values of 5, 6, 7, 8, 9, and 10, as well as any subranges such as 6 to 10, 7 to 10, 6 to 9, 7 to 9, etc.
- Inclusive and it will be understood to include any values between integers that are reasonable in the scope of the stated range, such as 5.5, 6.5, 7.5, 5.5 to 8.5 and 6.5 to 9, and the like.
- the range of "10% to 30%” is 10% to 15%, 12% to 10%, 11%, 12%, 13%, etc., as well as all integers including up to 30%. It will be understood to include any subranges such as 18%, 20% to 30%, and the like, and include any values between reasonable integers within the scope of the stated range, such as 10.5%, 15.5%, 25.5%, and the like.
- the present invention (a) Gujeolcho extract; Or (b) a mixture of Gujeolcho extract and malt extract; Or (c) it relates to a composition for preventing, improving or treating premenstrual syndrome comprising a mixture of Gujeolcho extract, malt extract and aloe extract.
- these compositions effectively inhibit the secretion of prolactin from pituitary cells, a phenomenon that occurs in premenstrual syndrome, and increase the secretion of progesterone lowered during the luteal phase of women, thereby being usefully used as a composition for preventing and improving or treating female premenstrual syndrome.
- Chrysanthemi Zawadskii Herba is a perennial herb belonging to the Asteraceae family, and uses outpost as a medicinal herb, and has been used in Chinese medicine and private sectors for pneumonia, bronchitis, bladder disease, uterine coldness, menstrual irregularities, gastrointestinal diseases, and high blood pressure.
- the main ingredients of Gujeolcho are linarin, a flavonoid compound, hydroxycoumarin, scopoletin and esculetin, which are coumarin compounds, polyacetylene compounds, sesquiterpene lactone compounds, angeloylcumambrin B, cumambrinA, and chamazulene, an essential oil component.
- Gujeolcho extract and linarin Anti-inflammatory, antipyretic and hepatoprotective action, sesquiterpene lactone is reported to have antitumor activity, cancer cell cytotoxicity, allelopathic action, antibacterial action and insecticidal action, as well as various pharmacological activities such as protective action, analgesic action, and antioxidant action of gastrointestinal cells.
- Gujeolcho of this material is a medicinal herb used in oriental medicine for menstrual impurities, but menstrual impurities are generally non-menstrual or irregular menstruation, and rare ovulation and aovulation belong to this.
- menstruation must be made, and it is a disease that is clearly distinguished from premenstrual syndrome, which shows breast tenderness and mental symptoms in the luteal phase before menstruation.
- premenstrual syndrome which shows breast tenderness and mental symptoms in the luteal phase before menstruation.
- Gujeolcho extract and its main components are effective in preventing, improving, or treating female premenstrual syndrome by inhibiting prolactin secretion.
- Malt (Hordei Fructus Germinatus), which is composed of the mixture of the present invention, is a medicinal herb made by sprouts of rice and stems, dried and slightly roasted. In oriental medicine, it has been used to treat digestive disorders caused by gastric weakness. Esau has been using malt. Wang et al. (2014) reported that malt water extract inhibited the secretion of prolactin by inducing dopamine receptor activation, and Sommer et al. (2017) reported that hordenine, a constituent of malt, was an agonist of dopamine receptors.
- the malt extract for the present invention when used in a mixture with Gujeolcho or aloe extract, more effectively inhibited the secretion of prolactin than the use of a single extract, in the present invention, it was composed of a mixture of compositions.
- Aloe is a perennial plant of the lily family and contains aloin (barbaloin), isobarbaloin, ⁇ -barbaloin, and resin. It has been traditionally used for skin diseases such as skin cancer, burns, eczema, psoriasis, etc. Antioxidant effect, wound healing effect, anti-constipation effect, antibacterial effect, and anti-osteoporosis effect have been reported.
- aloe extract was selected as a material capable of alleviating side effects that may occur when inhibiting prolactin secretion by applying the pituitary cell proliferation effect.However, when it is composed of Gujeolcho or malt, Gujeolcho, and a mixture with malt, the secretion of prolactin is more effective. Was suppressed, and accordingly constituted the composition of the present invention.
- no literature published to date revealed that aloe extract exhibits a proliferative effect of pituitary cells and is effective in preventing, improving, or treating female premenstrual syndrome by inhibiting prolactin secretion.
- the present invention provides a pharmaceutical composition for preventing and treating premenstrual syndrome comprising a mixture of Gujeolcho extract, Gujeolcho extract and malt extract, Gujeolcho extract, and a mixture of malt extract and aloe extract.
- the mixture may be an extract of Gujeolcho and malt or Gujeolcho and a mixture of malt and aloe, and may be a mixture of Gujeolcho extract and malt extract or Gujeolcho extract and malt extract and aloe extract.
- the Gujeolcho extract and malt extract may be in the form of a liquid extract or a lyophilized powder of the liquid extract
- the aloe extract may be in the form of a liquid extract or a lyophilized powder of the liquid extract, and freeze-drying of aloe It can be a powder.
- the present invention provides a health functional food composition for preventing and improving premenstrual syndrome comprising a mixture of Gujeolcho extract, Gujeolcho extract and malt extract, Gujeolcho extract and a mixture of malt extract and aloe extract.
- the mixture may be an extract of Gujeolcho and malt or Gujeolcho and a mixture of malt and aloe, and may be a mixture of Gujeolcho extract and malt extract or Gujeolcho extract and malt extract and aloe extract.
- the Gujeolcho extract, malt extract, and aloe extract may be in the form of a liquid extract or a lyophilized powder form of the liquid extract.
- One aspect of the present invention provides a composition for improving, preventing or treating premenstrual syndrome, comprising a Gujeolcho extract as an active ingredient.
- the composition provides a composition further comprising a malt extract.
- the active ingredient may be included in an amount of 20 to 60% by weight based on the total weight of the composition, but the present invention is not limited thereto.
- the composition provides a composition further comprising an aloe extract in addition to the malt extract.
- the active ingredient of the aloe extract may be included in an amount of 0 to 30% by weight based on the total weight of the composition, but the present invention is not limited thereto.
- compositions effectively inhibit the secretion of prolactin from pituitary cells and increase the secretion of progesterone in the luteal phase.
- the compositions are natural products that have been ingested and taken on a daily basis, and can be safely used for preventing, improving or treating premenstrual syndrome.
- the Gujeolcho extract may be obtained by extracting Gujeolcho by a conventional extraction method, and the extract may be an extract having a powdered form through a method of drying under reduced pressure and freeze drying.
- the malt extract may be obtained by extracting malt by a conventional extraction method, and the extract may be an extract having a powdered form through a method of drying under reduced pressure and freeze drying.
- the aloe extract may be extracted by a conventional extraction method, and the extract may be an extract having a powdered form through a method of drying under reduced pressure and freeze-drying, and freeze-dried immediately after peeling the aloe skin. It may be a powder.
- Gujeolcho extract and malt extract included in the mixture may be included in a ratio of 20 to 60% by weight, and aloe extract may be included in a ratio of 0 to 30% by weight.
- the extract provides a composition, which is a water extract, a C 1 -C 5 alcohol extract or a C 1 -C 5 alcohol aqueous solution extract.
- the composition for preventing, improving or treating premenstrual syndrome having the above composition of the present invention is obtained by extracting Gujeolcho, malt, aloe, respectively, or together with water, alcohol, alcohol, or a mixture thereof using an extraction solvent according to a conventional method.
- the extract may be obtained and used, and if necessary, the extraction process may be repeated, and the extract repeatedly extracted 2 to 5 times may be used.
- a dry powdery extract obtained by lyophilizing the extract may be prepared and used in the composition for preventing and improving or treating the premenstrual syndrome.
- the content of alcohol in the extraction solvent is 0 to 95% by weight of alcohol, preferably 30 to 70% by weight, more preferably 70% by weight of Gujeolcho, 50% by weight of malt, and 30% by weight of aloe. Maintaining is good in terms of extraction efficiency.
- alcohols may be applied as long as they are generally used in the art, and preferably alcohols having 1 to 5 carbon atoms, and the alcohol may be one or more selected from methanol, ethanol, isopropanol, propanol, and butanol. More preferably, ethanol, alcohol, etc. may be used as the alcohol.
- the extraction method is a method commonly known in the art, for example, a method using an extraction device such as supercritical extraction, subcritical extraction, high temperature extraction, high pressure extraction or ultrasonic extraction, or an adsorption resin including XAD and HP-20.
- a method of use or the like can be used.
- the extract is concentrated under reduced pressure using a vacuum rotary evaporator or the like to obtain an extract.
- the obtained extract may be dried under reduced pressure, vacuum drying, boiling drying, spray drying, room temperature drying, or freeze drying, if necessary.
- freeze-drying method when the freeze-drying method is applied, there is an advantage in that the loss of volatile organic substances in the extract can be reduced.
- Gujeolcho extract obtained through the above method effectively inhibits the secretion of prolactin in pituitary cells and increases the secretion of progesterone in the luteal phase.
- the composition of Gujeolcho extract and malt extract or Gujeolcho extract and malt extract and aloe extract obtained through the above method inhibits the secretion of prolactin in the pituitary gland cells and more effectively controls the secretion of progesterone.
- the Gujeolcho extract provides a composition of 0.001 to 90% by weight based on the total weight of the composition.
- the malt extract provides a composition comprising 50 to 150 parts by weight based on 100 parts by weight of Gujeolcho extract.
- the malt extract is included in an amount of 50 to 150 parts by weight based on 100 parts by weight of Gujeolcho extract
- the aloe extract is included in an amount of 10 to 30 parts by weight based on 100 parts by weight of Gujeolcho extract. do.
- composition comprising Gujeolcho extract, malt extract, and aloe extract is formed by satisfying the weight ratio as described above, it is possible to obtain a superior premenstrual syndrome prevention and treatment effect than when each is used.
- the Gujeolcho extract is a 60% to 80% ethanol aqueous solution extract
- the malt extract is a 40% to 60% ethanol aqueous solution extract
- the aloe extract is a 20% to 40% ethanol aqueous solution extract
- composition Provides.
- composition containing the Gujeolcho extract, the malt extract and the aloe extract is formed by satisfying the above content, it is possible to obtain a superior premenstrual syndrome prevention and treatment effect compared to the case of using each.
- the composition provides a composition, characterized in that it suppresses the secretion of prolactin or increases the secretion of progesterone in a woman in the luteal phase before menstruation.
- the symptoms of the premenstrual syndrome are minor psychological discomfort, bloating, weight gain, breast tenderness, muscle pain (muscular tension or aches). , Poor concentration and appetite change (change in appetite) any one or more of, and the premenstrual syndrome symptom is characterized in that it appears only in the luteal phase of the menstrual cycle, it provides a composition.
- the composition for preventing or treating premenstrual syndrome provides a pharmaceutical composition, a composition.
- the pharmaceutical composition When used clinically, it is mixed with a conventional carrier in the pharmaceutical field, such as tablets, capsules, powders, granules, pills, liquids, and suspensions.
- a conventional carrier in the pharmaceutical field
- Pharmaceutical preparations prepared by using conventional carriers can be administered orally or parenterally, for example, intravenously, subcutaneously, intraperitoneally or topically. Accordingly, the pharmaceutical composition of the present invention may further contain an appropriate carrier, excipient, and diluent commonly used in the manufacture of a medicament.
- Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate.
- Solid preparations for oral administration include tablets, pills, powders, granules, troches, rosin papers, capsules, and the like, and these solid preparations are at least one excipient in the composition of the present invention, such as lactose, saccharose, sorbitol. , Mannitol, starch, amylopectin, cellulose, calcium carbonate, gelatin, etc. are mixed and prepared.
- lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral administration include suspensions, solvents, emulsions, elixirs, syrups, etc., and various excipients in addition to water and liquid paraffin, which are commonly used simple diluents, such as humectants, sweeteners, fragrances, preservatives, etc. May be included.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, and suppositories.
- the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
- Parenteral administration may be generally administered by subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.
- the preferred dosage of the pharmaceutical composition of the present invention varies depending on the patient's age, weight, degree of disease, drug form, route and duration of administration, but may be appropriately selected by those skilled in the art. However, for a desirable effect, the pharmaceutical composition of the present invention may be administered at 0.01 mg/kg to 10 g/kg per day, preferably 1 mg/kg to 1 g/kg. Administration may be divided into several times a day, preferably once to six times, at regular time intervals according to the judgment of a doctor or pharmacist.
- the composition for improving the premenstrual syndrome provides a health functional food composition, a composition.
- the health functional food composition according to the present invention comprises a Gujeolcho extract or a mixture of Gujeolcho extract and malt extract, or a mixture of Gujeolcho extract, malt extract and aloe extract as an active ingredient, and can be consumed for the purpose of improving premenstrual conditions.
- the active ingredient may be ingested as a food prepared in tablets, capsules, powders, granules, pills, liquids, suspensions, or the like, or added to general foods. Since the health functional food uses food as a raw material, unlike general drugs, there is an advantage in that there are no side effects that may occur when taking the drug for a long time.
- the content of the active ingredient can be appropriately determined depending on the purpose of use (for prevention or improvement).
- the active ingredient may be contained in 0.1 to 90% by weight in the health functional food composition.
- the amount may be less than the above range, and there is no problem in terms of safety, so the active ingredient may be used in an amount above the above range.
- the type of the food There is no particular limitation on the type of the food.
- foods to which the active ingredient can be added include drinks, meat, sausage, bread, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, and various soups.
- Beverages, alcoholic beverages and vitamin complexes, dairy and dairy products, etc. and include all health functional foods in the usual sense.
- the properties of the food are not particularly limited, and may be solid, semi-solid, gel, liquid, powder, or the like.
- the beverage can be prepared as a beverage using the health functional food composition of the present invention.
- an ingredient included in the beverage there is no particular limitation on the selection of other ingredients other than the active ingredient, and as in ordinary beverages, various flavoring agents or natural carbohydrates may be included as additional ingredients.
- the natural carbohydrates described above include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavoring agents taumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)
- synthetic flavoring agents sacharin, aspartame, etc.
- the proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
- the health functional food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors and flavoring agents such as natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid, and Salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, etc. may be contained as additives. In addition, it may contain natural fruit juice and flesh for the production of fruit juice beverages and vegetable beverages. These components may be used independently or in combination. Although the proportion of these additives is not so important, it is generally selected in the range of 0.1 to 20% by weight in the health functional food composition of the present invention.
- Gujeolcho was purchased from Gyeongdong Market, and 1 kg of pulverized Gujeolcho was pulverized in the shade, and then extracted with 70% alcohol for 5 hours at 80°C, concentrated and freeze-dried to obtain 117.4 g (yield 11.7%) of Gujeolcho extract.
- Malt was purchased from Gyeongdong Market, and after crushing in the shade, 1 kg of crushed malt was extracted with 50% alcohol for 5 hours at 80°C, concentrated and freeze-dried to obtain 91.5 g (yield: 9.1%) of malt extract.
- Aloe was purchased from Samda Aloe Farm in Jeju, and after shaving in the shade, 1 kg of shredded aloe was extracted with 30% alcohol for 5 hours at 80° C., concentrated and freeze-dried to obtain 11.0 g of aloe extract (yield 1.1%).
- Rat pituitary cells GH3 were purchased from American Type Culture Collection (ATCC), and DMEM culture medium, trypsin, and Fetal bovine serum (FBS ) were purchased from GibcoTM (Invitrogen Corporation).
- GH3 pituitary cells were cultured in a DMEM medium containing 10% serum and antibiotics, and incubated in an incubator maintained at 37°C and supplied with 5% by volume of carbon dioxide. GH3 cells were dispensed into a 96 well plate at a concentration of 5 ⁇ 10 3 cells/well, and cultured for 24 hours. In order to measure the pituitary cell proliferation effect of the aloe extract, it was exchanged with DMEM medium containing 10% charcoaled FBS, and the aloe extract was treated at 25, 50, and 100 ⁇ g/mL, respectively. After 48 hours, the growth rate of GH3 cells was measured at an absorbance of 550 nm using an MTT reagent, and the absorbance of each test solution was measured based on the control group to indicate the cell proliferation rate (%).
- Table 2 shows the GH3 pituitary cell proliferation rate of the aloe extract.
- aloe showed the best pituitary cell proliferation efficacy in 30% alcohol extract, and showed a proliferation rate of about 136% compared to the control group.
- Test cells, medium and medium composition, and experimental conditions were the same as in Experimental Example 1, and a prolactin ELISA kit for measurement was purchased and used from Mol-innovation.
- GH3 pituitary cells were dispensed into a 24-well plate and cultured for 24 hours.
- each Gujeolcho extract and malt extract were treated at 25, 50, and 100 ⁇ g/mL, cultured for 48 hours, and then measured by substituting the amount of prolactin secretion into a standard curve using a rat prolactin ELISA kit.
- Table 3 shows the efficacy of Gujeolcho extract and malt extract to inhibit prolactin secretion.
- Gujeolcho showed an inhibitory rate of about 73.3% compared to the control group with the best prolactin secretion inhibitory effect in 70% alcohol extract.
- 100 ⁇ g in the extract extracted with 50% and 70% alcohol /mL concentration treatment showed similar efficacy, but 50 ⁇ g / mL concentration treatment showed better efficacy in the extract extracted with 50% alcohol. I wanted to.
- the present invention (a) Gujeolcho extract; Or (b) a mixture of Gujeolcho extract and malt extract; Or (c) a mixture of Gujeolcho extract, malt extract, and aloe extract may provide a composition for preventing and improving or treating premenstrual syndrome of the inhibitory effect of prolactin secretion in pituitary cells.
- Metoclopramide is a substance used as an emetic inhibitor and is known as a drug that increases the secretion of prolactin by inhibiting the secretion of dopamine, thereby inhibiting the secretion of progesterone, luteinizing hormone and follicle stimulating hormone (Wang et al. , 2014). Accordingly, in the present invention, an animal model of premenstrual syndrome according to hormone secretion disorder was established by inducing hyperprolactinemia after administration of metoclopramide at 50 mg/kg to the abdominal cavity of female rats for 5 days.
- Rats females were obtained through Raon Bio, and were purified for 1 week while supplying normal solid feed and water freely.
- the environmental conditions of the animal room were set to temperature 23 ⁇ 3°C, relative humidity 50 ⁇ 10%, lighting time 12 hours (8 am to 8 pm), ventilation frequency 10 to 20 times/hour, illuminance 150 to 300 Lux. .
- the temperature and humidity of the animal room were automatically controlled by a thermo-humidifier.
- mice were 1) normal group, 2) hyperprolactinemia induction control group, 3) Preparation Example 1 administration group, 4) Preparation Example 2 administration group, 5) Preparation Example 3 administration group, 6) 1:1 mixture of Preparation Examples 1 and 2 Administration group, 7) A 2:2:0.5 mixture administration group of Preparation Examples 1 and 2 and 3 (Preparation Example 4-12), groups 1 to 2 were administered saline, and the test substance administration groups 3 to 7 were all 100 mg/kg It was administered orally for 30 days at the concentration. After the end of the experiment, blood was collected, the serum was separated, and the amount of prolactin and progesterone secreted in the serum was measured using an ELISA kit, and the results are schematically shown in FIGS. 1 and 2.
- prolactin in serum was increased by metoclopramide, and was inhibited in all groups except for the 30% aloe extract of Preparation Example 3.
- the 70% alcohol extract of Gujeolcho of Preparation Example 1 exhibited a better inhibitory effect on prolactin secretion than the 50% malt alcohol extract of Preparation Example 2, and the mixture of Preparation Examples 1 and 2, and the mixture of Preparation Examples 1 and 2 and 3 In case, the secretion of prolactin was gradually reduced.
- progesterone in serum was reduced to about 1/5 by metoclopramide, and increased in all administration groups.
- the Gujeolcho 70% alcohol extract of Preparation Example 1 exhibited a better effect of increasing progesterone secretion than the malt 50% alcohol extract of Preparation Example 2, a mixture of Preparation Examples 1 and 2, and a mixture of Preparation Examples 1 and 2 and 3
- the concentration of progesterone was higher than that of Gujeolcho or malt or aloe extract alone.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
구절초70% 주정추출물 | 맥아50% 주정추출물 | 알로에30% 주정추출물 | |
4-1 | 1 | 0 | 0 |
4-2 | 0 | 1 | 0 |
4-3 | 0 | 0 | 1 |
4-4 | 1 | 1 | 0 |
4-5 | 0 | 1 | 1 |
4-6 | 1 | 0 | 1 |
4-7 | 1 | 1 | 1 |
4-8 | 2 | 1 | 1 |
4-7 | 1 | 2 | 1 |
4-10 | 1 | 1 | 2 |
4-11 | 2 | 2 | 1 |
4-12 | 2 | 2 | 0.5 |
4-13 | 1 | 2 | 2 |
4-14 | 2 | 1 | 2 |
4-15 | 3 | 1 | 1 |
4-16 | 3 | 2 | 1 |
4-17 | 2 | 3 | 1 |
4-18 | 1 | 3 | 1 |
시료 | 대조군 대비 뇌하수체 세포증식율 (%) | ||
25 μg/mL | 50 μg/mL | 100 μg/mL | |
알로에 열수추출물(비교예 9) | 104.1 ± 1.31 | 116.1 ± 2.02 | 124.2 ± 2.88 |
알로에 30% 주정추출물(제조예 3) | 106.8 ± 1.18 | 112.2 ± 2.90 | 136.0 ± 2.46 |
알로에 50% 주정추출물(비교예 10) | 98.3 ± 1.03 | 99.8 ± 3.28 | 132.5 ± 2.97 |
알로에 70% 주정추출물(비교예 11) | 101.4 ± 1.64 | 105.6 ± 2.15 | 122.5 ± 3.54 |
알로에 95% 주정추출물(비교예 12) | 96.4 ± 1.55 | 108.2 ± 2.56 | 116.4 ± 4.08 |
대조군 | 100.0 ± 3.69 |
시료 | 프로락틴 분비량 (ng/mL) | ||
25 μg/mL | 50 μg/mL | 100 μg/mL | |
구절초 열수추출물(비교예 1) | 1.81 ± 0.231 | 1.31 ± 0.188 | 1.19 ± 0.121 |
구절초 30% 주정추출물(비교예 2) | 1.74 ± 0.165 | 1.29 ± 0.132 | 1.00 ± 0.067 |
구절초 50% 주정추출물(비교예 3) | 1.90 ± 0.206 | 1.30 ± 0.101 | 1.00 ± 0.085 |
구절초 70% 주정추출물(제조예 1) | 1.72 ± 0.131 | 1.44 ± 0.213 | 0.43 ± 0.065 |
구절초 95% 주정추출물(비교예 4) | 1.63 ± 0.184 | 1.32 ± 0.152 | 0.61 ± 0.119 |
맥아 열수추출물(비교예 5) | 1.51 ± 0.132 | 1.18 ± 0.129 | 0.85 ± 0.063 |
맥아 30% 주정추출물(비교예 6) | 1.39 ± 0.079 | 1.08 ± 0.111 | 0.83 ± 0.036 |
맥아 50% 주정추출물(제조예 2) | 1.10 ± 0.022 | 0.91 ± 0.158 | 0.53 ± 0.036 |
맥아 70% 주정추출물(비교예 7) | 0.98 ± 0.268 | 0.96 ± 0.243 | 0.53 ± 0.019 |
맥아 95% 주정추출물(비교예 8) | 1.08 ± 0.231 | 0.89 ± 0.152 | 0.61 ± 0.094 |
대조군 | 1.61 ± 0.016 |
제조예1 | 제조예2 | 제조예3 | 프로락틴 분비량(ng/mL) | |
4-1 | 1 | 0 | 0 | 0.389 |
4-2 | 0 | 1 | 0 | 0.409 |
4-3 | 0 | 0 | 1 | 1.698 |
4-4 | 1 | 1 | 0 | 0.371 |
4-5 | 0 | 1 | 1 | 0.852 |
4-6 | 1 | 0 | 1 | 0.860 |
4-7 | 1 | 1 | 1 | 0.489 |
4-8 | 2 | 1 | 1 | 0.625 |
4-7 | 1 | 2 | 1 | 0.623 |
4-10 | 1 | 1 | 2 | 0.701 |
4-11 | 2 | 2 | 1 | 0.367 |
4-12 | 2 | 2 | 0.5 | 0.344 |
4-13 | 1 | 2 | 2 | 0.947 |
4-14 | 2 | 1 | 2 | 0.773 |
4-15 | 3 | 1 | 1 | 0.646 |
4-16 | 3 | 2 | 1 | 0.660 |
4-17 | 2 | 3 | 1 | 0.751 |
4-18 | 1 | 3 | 1 | 0.684 |
19 | 대조군 | 1.641 |
Claims (12)
- 구절초 추출물을 유효성분으로 포함하는, 월경전 증후군의 개선, 예방 또는 치료용 조성물.
- 제 1항에 있어서,상기 조성물은 맥아 추출물을 더 포함하는, 조성물.
- 제 2항에 있어서,상기 조성물은 알로에 추출물을 더 포함하는, 조성물.
- 제 1항에 있어서,상기 추출물은 물 추출물, C1-C5 알코올 추출물 또는 C1-C5 알코올 수용액 추출물인, 조성물.
- 제 1항에 있어서,상기 구절초 추출물은 조성물 전체 중량을 기준으로 0.001 내지 90 중량%인, 조성물.
- 제 2항에 있어서,상기 맥아 추출물은 구절초 추출물 100 중량부에 대하여 50 내지 150의 중량부로 포함되는, 조성물.
- 제 3항에 있어서,상기 맥아 추출물은 구절초 추출물 100 중량부에 대하여 50 내지 150의 중량부로 포함되고,상기 알로에 추출물은 구절초 추출물 100 중량부에 대하여 10 내지 30의 중량부로 포함되는, 조성물.
- 제 3항에 있어서,상기 구절초 추출물은 60% 내지 80% 에탄올 수용액 추출물이며,상기 맥아 추출물은 40% 내지 60% 에탄올 수용액 추출물이고,상기 알로에 추출물은 20% 내지 40% 에탄올 수용액 추출물인, 조성물.
- 제1항에 있어서,상기 조성물은 월경전 황체기의 여성에게 있어서 프로락틴 분비를 억제하거나 프로게스테론의 분비를 증가시키는 것을 특징으로 하는, 조성물.
- 제1항에 있어서,상기 월경전 증후군의 증상은 경미한 정신적 장애 (minor psychological discomfort), 더부룩함 (bloating), 체중 증가 (weight gain), 유방 압통 (breast tenderness), 근육통 (muscular tension or aches), 집중력 저하 (poor concentration) 및 식욕 변화 (change in appetite) 중 어느 하나 이상이며,상기 월경전 증후군 증상은 월경 주기 중 황체기에만 나타나는 것을 특징으로 하는, 조성물.
- 제 1항 내지 제 10항 중 어느 한 항에 있어서,상기 월경전 증후군 예방 또는 치료용 조성물은 약학 조성물인, 조성물.
- 제 1항 내지 제 10항 중 어느 한 항에 있어서,상기 월경전 증후군 개선용 조성물은 건강기능 식품 조성물인, 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019464462A AU2019464462A1 (en) | 2019-09-03 | 2019-09-03 | Composition for ameliorating premenstrual syndrome symptoms, including chrysanthemum sibiricum extract |
PCT/KR2019/011306 WO2021045242A2 (ko) | 2019-09-03 | 2019-09-03 | 구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 |
CA3149197A CA3149197A1 (en) | 2019-09-03 | 2019-09-03 | Composition for ameliorating premenstrual syndrome symptoms, including chrysanthemum zawadskii extract |
EP19943918.3A EP4026552A4 (en) | 2019-09-03 | 2019-09-03 | PREMENSTRUAL SYNDROME SYMPTOMS IMPROVING COMPOSITION COMPRISING CHRYSANTHEMUM SIBIRICUM EXTRACT |
JP2022514010A JP7312907B2 (ja) | 2019-09-03 | 2019-09-03 | チョウセンノギク抽出物を含む月経前症候群症状改善用組成物 |
US17/637,915 US20220280583A1 (en) | 2019-09-03 | 2019-09-03 | Composition for ameliorating premenstrual syndrome symptoms, including chrysanthemum zawadskii extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2019/011306 WO2021045242A2 (ko) | 2019-09-03 | 2019-09-03 | 구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021045242A2 true WO2021045242A2 (ko) | 2021-03-11 |
WO2021045242A3 WO2021045242A3 (ko) | 2021-04-29 |
Family
ID=74853344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/011306 WO2021045242A2 (ko) | 2019-09-03 | 2019-09-03 | 구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220280583A1 (ko) |
EP (1) | EP4026552A4 (ko) |
JP (1) | JP7312907B2 (ko) |
AU (1) | AU2019464462A1 (ko) |
CA (1) | CA3149197A1 (ko) |
WO (1) | WO2021045242A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4205558A4 (en) * | 2020-08-31 | 2024-01-24 | Green Cross Wellbeing Corp | FUNCTIONAL HEALTH FOOD, INCLUDING SIBERIAN CHRYSANTHEMUM EXTRACT, FOR PAIN RELIEF OR ANTIOXIDATION |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100044433A (ko) | 2008-10-22 | 2010-04-30 | 주식회사 유영제약 | 구절초 추출물 또는 분획물을 유효성분으로 함유하는 위장관 질환의 예방 및 치료용 조성물 |
KR20130076114A (ko) | 2011-12-28 | 2013-07-08 | 유은미 | 구절초 및 아로니아로 구성되는 혼합 추출물을 함유하는 화장료 조성물 |
KR20130092256A (ko) | 2012-02-10 | 2013-08-20 | 애경산업(주) | 발모 및 육모 촉진용 조성물 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960003883B1 (ko) * | 1992-12-14 | 1996-03-23 | 주식회사김정문알로에 | 알로에 베라겔 용액의 제조방법 |
KR100565414B1 (ko) * | 2003-12-12 | 2006-03-30 | (주) 영평식품 | 음용이 용이한 구절초 액상 조성물 |
JP5066346B2 (ja) * | 2006-07-11 | 2012-11-07 | 株式会社健康家族 | 月経痛及び/又は月経前症候群の症状の予防及び/又は治療用組成物 |
CN101919979B (zh) * | 2009-06-11 | 2012-08-15 | 北京亚东生物制药有限公司 | 一种疏肝解郁,健脾利湿的中药组合物的检测方法 |
KR101180442B1 (ko) * | 2009-11-05 | 2012-09-06 | 박명희 | 구절초와 옥수수를 이용한 고추장의 제조방법 |
KR20130086682A (ko) * | 2012-01-26 | 2013-08-05 | 한국스포츠생명공학협회 | 골장회복 하수오와 홍삼녹용과 오가피등 100가지한약재 추출물 드링크제 및제조 방법 |
KR101340040B1 (ko) * | 2013-04-05 | 2013-12-10 | 김호현 | 맥아 추출물을 유효성분으로 포함하는 비만 및 대사성 질환 예방 및 치료용 조성물 |
KR102132655B1 (ko) * | 2016-05-26 | 2020-07-13 | 콜마비앤에이치 주식회사 | 구절초 추출물을 포함하는 조성물 |
WO2018030650A1 (ko) * | 2016-08-12 | 2018-02-15 | 경북대학교 산학협력단 | 국화잎 추출물을 유효성분으로 포함하는 항비만 조성물 |
KR101841137B1 (ko) * | 2017-01-26 | 2018-03-23 | 주식회사 에코마인 | 여성 청결제 조성물 및 그 제조방법 |
KR102053700B1 (ko) * | 2017-09-29 | 2019-12-09 | 농업회사법인 아나덤 주식회사 | 구절초 추출물의 제조 방법 |
KR102045903B1 (ko) * | 2018-03-07 | 2019-11-18 | 주식회사 제넨셀 | 구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 |
KR102331317B1 (ko) * | 2019-02-25 | 2021-11-26 | 주식회사 제넨셀 | 구절초 추출물로부터 분리된 화합물을 유효성분으로 포함하는 월경전 증후군 증상 개선용 조성물 |
-
2019
- 2019-09-03 WO PCT/KR2019/011306 patent/WO2021045242A2/ko unknown
- 2019-09-03 EP EP19943918.3A patent/EP4026552A4/en active Pending
- 2019-09-03 US US17/637,915 patent/US20220280583A1/en active Pending
- 2019-09-03 CA CA3149197A patent/CA3149197A1/en active Pending
- 2019-09-03 JP JP2022514010A patent/JP7312907B2/ja active Active
- 2019-09-03 AU AU2019464462A patent/AU2019464462A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100044433A (ko) | 2008-10-22 | 2010-04-30 | 주식회사 유영제약 | 구절초 추출물 또는 분획물을 유효성분으로 함유하는 위장관 질환의 예방 및 치료용 조성물 |
KR20130076114A (ko) | 2011-12-28 | 2013-07-08 | 유은미 | 구절초 및 아로니아로 구성되는 혼합 추출물을 함유하는 화장료 조성물 |
KR20130092256A (ko) | 2012-02-10 | 2013-08-20 | 애경산업(주) | 발모 및 육모 촉진용 조성물 |
Non-Patent Citations (1)
Title |
---|
See also references of EP4026552A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4205558A4 (en) * | 2020-08-31 | 2024-01-24 | Green Cross Wellbeing Corp | FUNCTIONAL HEALTH FOOD, INCLUDING SIBERIAN CHRYSANTHEMUM EXTRACT, FOR PAIN RELIEF OR ANTIOXIDATION |
Also Published As
Publication number | Publication date |
---|---|
EP4026552A4 (en) | 2023-05-10 |
JP7312907B2 (ja) | 2023-07-21 |
CA3149197A1 (en) | 2021-03-11 |
AU2019464462A1 (en) | 2022-03-24 |
WO2021045242A3 (ko) | 2021-04-29 |
EP4026552A2 (en) | 2022-07-13 |
JP2022546536A (ja) | 2022-11-04 |
US20220280583A1 (en) | 2022-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100847343B1 (ko) | 생약복합재 추출물을 함유하는 골길이 성장 촉진용 조성물 | |
KR100900836B1 (ko) | 생약복합재 추출물을 함유하는 골길이 성장 촉진용 약학적조성물 | |
KR102045903B1 (ko) | 구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 | |
WO2015002391A1 (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 | |
WO2018174448A1 (ko) | 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합생약 추출물을 유효성분으로 함유하는 갱년기증후군의 치료 및 예방을 위한 조성물 및 이의 용도 | |
WO2021201532A1 (ko) | 해당화 추출물을 유효성분으로 포함하는 여성 폐경기 증후군 예방, 개선 또는 치료용 조성물 | |
WO2014200234A1 (ko) | 지황 및 갈근의 복합 추출물을 함유하는 갱년기 증상의 예방 또는 치료용 조성물 | |
WO2016186349A2 (ko) | 사군자 추출물을 함유하는 전립선 비대증 예방 또는 치료용 조성물 | |
KR102187335B1 (ko) | 맥아 추출물로부터 분리된 화합물을 유효성분으로 포함하는 월경전 증후군 증상 개선용 조성물 | |
WO2021045242A2 (ko) | 구절초 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 | |
KR102331317B1 (ko) | 구절초 추출물로부터 분리된 화합물을 유효성분으로 포함하는 월경전 증후군 증상 개선용 조성물 | |
WO2021149902A1 (ko) | 단삼 추출물을 유효성분으로 포함하는 폐경기 여성의 우울증 예방 및 치료용 조성물 | |
WO2021080297A1 (ko) | 달맞이꽃 추출물을 유효성분으로 포함하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물 | |
WO2020080673A1 (ko) | 병풀 추출물을 포함하는 망막 질환의 예방 또는 치료용 조성물 | |
WO2020122385A1 (ko) | 목향 추출물을 포함하는 월경전 증후군 증상 개선용 조성물 | |
WO2020241958A1 (ko) | 동충하초 농축액을 유효성분으로 포함하는 여성 갱년기 증상 예방 또는 치료용 조성물 | |
WO2010008150A2 (ko) | 삼백초와 황금의 혼합 추출물을 유효성분으로 함유하는 골다공증 예방 또는 치료용 조성물 | |
WO2018008973A1 (ko) | 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물 | |
WO2022216107A1 (ko) | 담팔수 추출물 또는 이의 정제물을 유효성분으로 함유하는 항암용 조성물 | |
KR20040082951A (ko) | 감초 추출물 또는 이솔리퀴리틴을 포함하는파이토에스트로젠 조성물 | |
WO2013022178A1 (ko) | 발효 또는 미발효된 금은화 및 진피 혼합생약 추출물을 유효성분으로 함유하는 비만증의 예방 및 치료용 조성물 및 이의 용도 | |
KR20210063044A (ko) | 지황 추출물을 유효성분으로 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물 | |
KR20080109360A (ko) | 복합생약재 추출물을 함유하는 골길이 성장 촉진용 약학적 조성물 | |
WO2023043171A1 (ko) | 칡발효물을 유효성분으로 포함하는 월경전증후군의 개선, 예방 또는 치료용 조성물 | |
KR100997215B1 (ko) | 황기 생약추출물 또는 이로부터 분리된 에틸아세테이트분획물을 함유하는 골길이 성장 장애 치료 및 예방용약학조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19943918 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 3149197 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022514010 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019464462 Country of ref document: AU Date of ref document: 20190903 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019943918 Country of ref document: EP Effective date: 20220404 |